Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine? - Approximating the funding to the University of Oxford for the research and development of the ChAdOx vaccine technology
Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine? - Approximating the funding to the University of Oxford for the research and development of the ChAdOx vaccine technology
复制标题
谁资助了牛津-阿斯利康 COVID-19 疫苗的研究？
DOI：
--
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
S. Keestra
中科院分区：
文献类型：
--
作者：
Samuel Cross;Y. Rho;Henna Reddy;Toby Pepperrell;F. Rodgers;Rhiannon Osborne;Ayolola Eni;R. Banerjee;Sabrina Wimmer;S. Keestra
目的：牛津-阿斯利康新冠肺炎疫苗(ChAdOx1nCoV-19或Vaxzevira)建立在牛津大学近20年来研发黑猩猩腺病毒载体疫苗(ChAdOx)技术的基础上。这项研究旨在近似ChAdOx技术和牛津-阿斯利康疫苗的研发资金，并评估资金报告机制的透明度。设计：我们对主要研究人员进行了范围审查和发表历史分析，以重建ChAdOx技术研发的资金来源。我们将奖励数字与公众可访问的赠款数据库进行了匹配。我们向牛津大学提交了信息自由(FOI)请求，要求披露对ChAdOx研发的所有拨款。结果：我们确定了在2002年1月至2020年10月发表的100篇与ChAdOx技术相关的同行评议文章，从资助确认书中提取了577条提到资助机构的信息。来自海外的政府资助者被提及158次(27.4%)，英国政府被提及147(25.5%)，慈善资助者被提及138(23.9%)。确定了215次(37.3%)提及的授予奖编号，121次(21.0%)提及了公共领域的金额。根据FOIS，直到2020年1月，欧盟委员会(34.0%)、惠康信托(20.4%)和CEPI(17.5%)是ChAdOx研发的最大资助者。从2020年1月起，英国卫生和社会保健部是最大的资助者(89.3%)。确定的研发资金是FOIS报告的104,226,076英镑，根据文献搜索重建的28,466,771英镑。结论：我们的研究发现，公共资金占ChAdOx和牛津-阿斯利康疫苗研发资金的97.1-99.0%。此外，我们还遇到研究经费报告机制严重缺乏透明度的问题。
Objectives: The Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19 or Vaxzevira) builds on nearly two decades of research and development (R&D) into Chimpanzee adenovirus-vectored vaccine (ChAdOx) technology at the University of Oxford. This study aims to approximate the funding for the R&D of the ChAdOx technology and the Oxford-AstraZeneca vaccine, and assess the transparency of funding reporting mechanisms. Design: We conducted a scoping review and publication history analysis of the principal investigators to reconstruct the funding for the R&D of the ChAdOx technology. We matched award numbers with publicly-accessible grant databases. We filed Freedom Of Information (FOI) requests to the University of Oxford for the disclosure of all grants for ChAdOx R&D. Results: We identified 100 peer-reviewed articles relevant to ChAdOx technology published between 01/2002 and 10/2020, extracting 577 mentions of funding bodies from funding acknowledgement statements. Government funders from overseas were mentioned 158 (27.4%), the U.K. government 147 (25.5%) and charitable funders 138 (23.9%) times. Grant award numbers were identified for 215 (37.3%) mentions, amounts were available in the public realm for 121 (21.0%) mentions. Based on the FOIs, until 01/2020, the European Commision (34.0%), Wellcome Trust (20.4%) and CEPI (17.5%) were the biggest funders of ChAdOx R&D. From 01/2020, the U.K. Department of Health and Social Care was the single largest funder (89.3%). The identified R&D funding was GBP104,226,076 reported in the FOIs, and GBP228,466,771 reconstructed from the literature search. Conclusions: Our study identified that public funding accounted for 97.1-99.0% of the funding towards the R&D of ChAdOx and the Oxford-AstraZeneca vaccine. We furthermore encountered a severe lack of transparency in research funding reporting mechanisms.
DOI：
10.1016/s0140-6736(20)32466-1
发表时间：
2021-12-19
期刊：
Lancet (London, England)
影响因子：
--
作者：
Ramasamy MN;Minassian AM;Ewer KJ;Flaxman AL;Folegatti PM;Owens DR;Voysey M;Aley PK;Angus B;Babbage G;Belij-Rammerstorfer S;Berry L;Bibi S;Bittaye M;Cathie K;Chappell H;Charlton S;Cicconi P;Clutterbuck EA;Colin-Jones R;Dold C;Emary KRW;Fedosyuk S;Fuskova M;Gbesemete D;Green C;Hallis B;Hou MM;Jenkin D;Joe CCD;Kelly EJ;Kerridge S;Lawrie AM;Lelliott A;Lwin MN;Makinson R;Marchevsky NG;Mujadidi Y;Munro APS;Pacurar M;Plested E;Rand J;Rawlinson T;Rhead S;Robinson H;Ritchie AJ;Ross-Russell AL;Saich S;Singh N;Smith CC;Snape MD;Song R;Tarrant R;Themistocleous Y;Thomas KM;Villafana TL;Warren SC;Watson MEE;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Faust SN;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
DOI：
10.1056/nejmoa1411627
发表时间：
2016-04-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Ewer K;Rampling T;Venkatraman N;Bowyer G;Wright D;Lambe T;Imoukhuede EB;Payne R;Fehling SK;Strecker T;Biedenkopf N;Krähling V;Tully CM;Edwards NJ;Bentley EM;Samuel D;Labbé G;Jin J;Gibani M;Minhinnick A;Wilkie M;Poulton I;Lella N;Roberts R;Hartnell F;Bliss C;Sierra-Davidson K;Powlson J;Berrie E;Tedder R;Roman F;De Ryck I;Nicosia A;Sullivan NJ;Stanley DA;Mbaya OT;Ledgerwood JE;Schwartz RM;Siani L;Colloca S;Folgori A;Di Marco S;Cortese R;Wright E;Becker S;Graham BS;Koup RA;Levine MM;Volkmann A;Chaplin P;Pollard AJ;Draper SJ;Ballou WR;Lawrie A;Gilbert SC;Hill AV
通讯作者：
Hill AV